Ikena Oncology to Participate in Spring 2022 Investor Conferences
May 18 2022 - 7:00AM
Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology
company forging new territory in patient-directed cancer treatment,
today announced that management will be presenting at the H.C.
Wainwright Global Investment Conference, taking place May 23-26,
2022, and the Jefferies Global Healthcare Conference, taking place
June 8-10, 2022.
Ikena CEO Mark Manfredi, Ph.D., will present a
corporate update at the H.C. Wainwright Global Investment
Conference and management will attend virtually. They will also
participate in a fireside chat at the Jefferies Global Healthcare
Conference and will attend the conference live in New York
City.
Details can be found below:
H.C
Wainwright Global Investment Conference |
Corporate Presentation |
Date: May 25, 2022, 11:30 a.m. ET |
Webcast Link |
Jefferies Global Healthcare Conference |
Fireside Chat |
Date: June 9, 2022, 10:00 a.m. ET |
Webcast Link |
The presentation webcasts will be available on the
Company’s Events & Presentations page on their website at
www.ikenaoncology.com.
About Ikena OncologyIkena
OncologyTM is focused on developing novel therapies targeting key
signaling pathways that drive the formation and spread of cancer.
The Company’s lead targeted oncology program, IK-930, is a TEAD
inhibitor addressing the Hippo signaling pathway, a known tumor
suppressor pathway that also drives resistance to multiple targeted
therapies. The Company’s ongoing discovery research spans other
targets in the Hippo pathway as well as the RAS signaling pathway.
Additional programs targeting the tumor microenvironment and immune
signaling are in the clinic, including IK-175, an aryl hydrocarbon
receptor antagonist, which is being developed in collaboration with
Bristol Myers Squibb. Ikena’s pipeline is built on addressing
genetically defined or biomarker-driven cancers and developing
therapies that can serve specific patient populations in need of
new therapeutic options. To learn more,
visit www.ikenaoncology.com or follow us on Twitter and
LinkedIn.
Investor Contact:Rebecca
CohenIkena Oncologyrcohen@ikenaoncology.com
Media Contact:Gwen SchankerLifeSci
Communicationsgschanker@lifescicomms.com
Ikena Oncology (NASDAQ:IKNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ikena Oncology (NASDAQ:IKNA)
Historical Stock Chart
From Apr 2023 to Apr 2024